Mustang Bio Statistics
Share Statistics
Mustang Bio has 48.77M shares outstanding. The number of shares has increased by 334.64% in one year.
| Shares Outstanding | 48.77M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 19.62% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 45.93M |
| Failed to Deliver (FTD) Shares | 63.18K |
| FTD / Avg. Volume | 3.39% |
Short Selling Information
The latest short interest is 534.21K, so 1.14% of the outstanding shares have been sold short.
| Short Interest | 534.21K |
| Short % of Shares Out | 1.14% |
| Short % of Float | 1.23% |
| Short Ratio (days to cover) | 0.15 |
Valuation Ratios
The PE ratio is -0.23 and the forward PE ratio is -0.73.
| PE Ratio | -0.23 |
| Forward PE | -0.73 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 94.44 |
| P/FCF Ratio | -0.23 |
| PEG Ratio | n/a |
Enterprise Valuation
Mustang Bio Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 4.23.
| Current Ratio | 0.74 |
| Quick Ratio | 0.74 |
| Debt / Equity | 4.23 |
| Total Debt / Capitalization | 80.87 |
| Cash Flow / Debt | -95.15 |
| Interest Coverage | -38.6 |
Financial Efficiency
Return on equity (ROE) is -419.53% and return on capital (ROIC) is -1935.37%.
| Return on Equity (ROE) | -419.53% |
| Return on Assets (ROA) | -2.91% |
| Return on Capital (ROIC) | -1935.37% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -645.02K |
| Employee Count | 80 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -86.23% in the last 52 weeks. The beta is 1.92, so Mustang Bio 's price volatility has been higher than the market average.
| Beta | 1.92 |
| 52-Week Price Change | -86.23% |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | 0.4 |
| Relative Strength Index (RSI) | 41.26 |
| Average Volume (20 Days) | 1.86M |
Income Statement
In the last 12 months, Mustang Bio had revenue of $0 and earned -$51.60M in profits. Earnings per share was $-6.
| Revenue | 0 |
| Gross Profit | -2.23M |
| Operating Income | -50.73M |
| Net Income | -51.60M |
| EBITDA | -48.06M |
| EBIT | - |
| Earnings Per Share (EPS) | -6 |
Balance Sheet
The company has $6.23M in cash and $2.50M in debt, giving a net cash position of $3.74M.
| Cash & Cash Equivalents | 6.23M |
| Total Debt | 2.50M |
| Net Cash | 3.74M |
| Retained Earnings | -380.97M |
| Total Assets | 7.19M |
| Working Capital | -8.98M |
Cash Flow
In the last 12 months, operating cash flow was -$49.48M and capital expenditures -$114.00K, giving a free cash flow of -$49.59M.
| Operating Cash Flow | -49.48M |
| Capital Expenditures | -114.00K |
| Free Cash Flow | -49.59M |
| FCF Per Share | -5.76 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
MBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3157.89% |
| FCF Yield | -525.77% |
Analyst Forecast
The average price target for MBIO is $2, which is 952.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $2 |
| Price Target Difference | 952.6% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Apr 4, 2023. It was a backward split with a ratio of 1:15.
| Last Split Date | Apr 4, 2023 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -88.5 |
| Piotroski F-Score | 2 |